ANN ARBOR, Mich., Dec. 7 (UPI) -- U.S. medical researchers have created a new therapy for patients suffering pulmonary arterial hypertension, or PAH.The University of Michigan scientists found adding inhaled iloprost to treatment with bosentan -- two different classes of drugs often used individually to treat PAH -- increases exercise capability, reduces clinical deterioration and, in some cases, improves diagnostic functional class by one stage.>>> Discuss This Story
